The trail demonstrates that a swallowable, low-pill, non-absorbed iron polymer can match or exceed sevelamer in phosphate control.

ANI Pharmaceuticals has disclosed the outcomes of its NEW DAY trial, assessing Iluvien 0.19mg, in people with diabetic macular oedema.

Abivax's obefazimod resulted in an average 16.4% placebo-adjusted clinical remission rate in UC patients across the two trials.

Combining Scancell's melanoma drug iSCIB1+ with Yervoy and Opdivo significantly improved patient overall response rate.

Arch Biopartners has initiated subject recruitment in its Phase II study aimed at assessing cilastatin in preventing AKI.

AstraZeneca's Tagrisso combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS).

Diakonos Oncology has dosed the first subject in its Phase II trial of DOC1021 for treating glioblastoma (GBM).

Monte Rosa Therapeutics has dosed the first participants in the Phase I trial of the NEK7-directed molecular glue degrader (MGD), MRT-8102.

Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.

The first patient has been treated with InterVene’s Recana thrombectomy system for restoring patency (blood flow) in chronically obstructed deep veins and venous stents.

Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.

New guidelines recommended by WHO will need to be backed with funding to be implemented at scale in affected communities.